Stony Brook - 3 years ago

Two years after receiving FDA approval as the U.S. s first non-surgical treatment of Dupuytren s disease, a drug called XIAFLEX® (collagenase clostridium histolyticum or CCH), developed at Stony Brook University has already been administered to over 20,000 patients in the U.S. as treatment for the debilitating hand disorder. XIAFLEX, marketed and distributed in the U.S. by Auxilium Pharmaceuticals, Inc. (Malvern, PA), is indicated for the treatment of adult patients with Dupuytren s contracture with a palpable cord. Now, the drug is being marketed internationally to patients who are afflicted and it is in early-stage testing for potential new applications - including treatment of cellulite as a cosmetic procedure - according to researchers at Stony Brook University School of Medicine.

Latest News

Hashtags:   

Stony

 | 

Brook

 | 

Researchers

 | 

International

 | 

Markets

 | 

Applications

 | 

Frozen

 | 

Shoulder

 | 

Cellulite

 | 

Possible

 | 

Sources